|
CARLOS M FERRARIO, M.D.
Professor and Director,
Hypertension and Vascular Research Center
Professor, Department of Physiology/Pharmacology
Wake Forest University School of Medicine
President and CEO,
Consortium for Southeastern Hypertension Control
Medical Center Boulevard
Winston-Salem, NC 27157-1032
Tel: 336-716-5819
Fax: 336-716-6644
E-mail: cferrari@wfubmc.edu
Center for Excellence in Hypertension and Vascular Research |
Education:
M Moreno College, Argentina, BA, 1956
University of Buenos Aires School of Medicine, MD, 1963
Research Description:
Cardiovascular Medicine
Hemodynamics of Hypertension
Hormonal Regulation of Blood Pressure
Vascular Disease
Current Research:
Elucidation of the mechanisms of hypertensive vascular disease by combining laboratory efforts with clinical investigation utilizing molecular, genetic, and physiological approaches to the characterization of cardiac and blood vessel remodeling;
Study of the function of angiotensin peptides, with special emphasis on angiotensin-(1-7) in the regulation of blood pressure;
Analysis of the mechanism of action of antihypertensive drugs such as angiotensin converting enzyme inhibitors and angiotensin II antagonists in reversing the cardiac and vascular sequelae of hypertension and the metabolic syndrome.
Dr. Ferrario has published 400 papers to-date in the field of hypertension and vascular disease. He serves as officer and member of many professional societies and has been bestowed multiple national and international awards.
He is the Founder of the Consortium for Southeastern Hypertension Control (COSEHC), an organization which has pioneered medical and educational efforts directed to reduce cardiovascular deaths in the South.
Recent Publications:
For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine.
Morris RT, Fine DM, Lees SJ, Booth FW, Link CD, Ferrario CM, Stump CS, Sowers JR. Exercise training prevents development of cardiac contractile dysfunction in hypertensive TG (mREN-2)27 rats. J Am Soc Hypertens. 2007 Dec;1(6):393-399.
Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2373-9.
Gallagher PE, Ferrario CM, Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol. 2008 Nov;295(5):C1169-74.
Habibi J, Whaley-Connell A, Hayden MR, DeMarco VG, Schneider R, Sowers SD, Karuparthi P, Ferrario CM, Sowers JR. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology. 2008 Nov;149(11):5643-53.
Igase M, Kohara K, Nagai T, Miki T, Ferrario CM. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res. 2008 Mar;31(3):553-9
Smith RD, Yokoyama H, Averill DB, Cooke L, Brosnihan KB, Schiffrin EL, Ferrario CM. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs. 2006;6(5):335-42.